Evidence map›Paper›PMID 42102522›Full record

ArticleGynecologic oncology2026

Risk-reducing gynecologic surgery decisions in Lynch syndrome at a safety-net hospital and university medical center.

Rebecca M Waggoner, Charité N Ricker, Qi Nie, X Mona Guo, Jacob G Comeaux, Emmeline Y Chang, Natalia Gutierrez, Daisy Hernandez, Averi Nguyen, Ivan Garcia and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rebecca M WaggonerDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Electronic address: rebecca.waggoner@med.usc.edu.
Charité N RickerDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA; Los Angeles General Medical Center, Los Angeles, USA.
Qi NieUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA.
X Mona GuoUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA; Los Angeles General Medical Center, Los Angeles, USA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Jacob G ComeauxDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Emmeline Y ChangDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Natalia GutierrezDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; Los Angeles General Medical Center, Los Angeles, USA.
Daisy HernandezDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; Los Angeles General Medical Center, Los Angeles, USA.
Averi NguyenDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Ivan GarciaDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Fumito ItoUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA; Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; Department of Immunology & Immune Therapeutics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Laurie L BrunetteDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Lynda D RomanUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA; Los Angeles General Medical Center, Los Angeles, USA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, California, USA.
Darcy SpicerDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA; Los Angeles General Medical Center, Los Angeles, USA.
Julie O CulverDivision of Medical Oncology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy AssayR01CA272827 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DY, GRACE, ITO, FUMITO · 2022 to 2025
$3.1M
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumorsR01CA255240 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ITO, FUMITO · 2021 to 2025
$2.0M
NCI NIH HHS P30 CA014089NCI NIH HHS R01 CA255240NCI NIH HHS R01 CA272827
6 · The paper itself

Abstract

objectiveTo explore uptake of risk-reducing gynecologic surgery in a diverse patient population with Lynch syndrome.

methodsChart reviews of women with Lynch syndrome were conducted at a safety-net hospital and university medical center, including women over age 30 with an intact uterus and/or ovaries and no prior history of uterine or ovarian cancer. Potential factors associated with uptake of surgery and time to risk-reducing surgery were analyzed.

resultsThe 65 women studied included 27 (41.5%) White, non-Hispanic, 30 (46.2%) Hispanic, 5 (7.7%) Asian, and 3 (4.6%) other. The diagnosis of Lynch syndrome was made at a median of 41.0 years (IQR 31.0 to 48.0) with pathogenic variants in MLH1 (27, 41.5%), MSH2 (14, 21.5%), MSH6 (5, 7.7%), PMS2 (17, 26.2%), or EPCAM (2, 3.1%). The majority (35, 53.8%) had a history of colon or other cancer, and 24 (36.9%) were Spanish-language preferring. Safety-net hospital patients were more likely to undergo risk-reducing surgery (19/28, 67.9%) compared to university medical center patients (13/37, 35.1%), even when controlling for age and prior history of non-gynecologic cancer (HR = 2.43, p = 0.02). Safety-net hospital patients also demonstrated quicker uptake of surgery (p = 0.005). Age, parity, Lynch-associated gene, benign gynecologic diagnosis, family history, race/ethnicity, or language preference were not significantly associated with undergoing surgery.

conclusionThis exploratory analysis suggested a higher uptake of risk-reducing surgery at the safety-net hospital than at the university medical center. Understanding factors contributing to this difference will be critical to supporting gynecologic cancer risk management in Lynch syndrome.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisGenital Neoplasms, FemaleGynecologic Surgical ProceduresProphylactic Surgical ProceduresAcademic Medical CentersAdultFemaleHumansMiddle AgedSafety-net ProvidersDecision-makingGynecologic cancerLynch syndromeRisk-reductionSurveillance

Identifiers

PMID42102522
PMCPMC13267529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.